Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
調査の概要
詳細な説明
The aim of the study is to assess whether patients fulfilling the criteria as defined in section 3 will benefit from a treatment with ribavirin/PEG-a-IFN combined treatment. This study will be open to all patients with histologically documented hepatitis C recurring after LT, provided that all inclusion and exclusion criteria, as defined below, are met, and irrespectively of the pattern of response to a previous antiviral treatment (if any).
The benefit will be assessed in terms of biochemical (normalization of serum transaminases levels), virological (disappearance of HCV RNA from serum) and histological (amelioration of the histological signs of hepatitis) response. The presence of a sustained virological response, as defined below in section 6, will also be studied in relation to the early kinetics of serum HCV RNA, in keeping with recent data obtained in chronic hepatitis C patients, which suggest that an early rapid decrease of HCV viremia is associated with a durable response.
研究の種類
入学
段階
- フェーズ 3
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 to 65 year old patients, male or female, having undergone a LT for end-stage liver disease due to HCV
- patients presenting after LT with recurrent HCV infection, documented by presence of HCV RNA in serum, and recurrent hepatitis, diagnosed at histology; the liver biopsy upon which the diagnosis is established must have been performed within the 12 months prior to inclusion; the treatment cannot start within the 6 months following LT
- alpha fetoprotein value within normal limits obtained within 3 months before entry visit
- stable immunosuppressive regimen, defined as lack of any therapeutic measures aimed at preventing or treating graft rejection during the three months prior to antiviral therapy
Exclusion Criteria:
- participation in other clinical trial within 30 days of entry into this protocol
- patients retransplanted for rejection or for recurrent hepatitis C on the graft
- patients with a history of cardiovascular disease including but not limited to uncontrolled hypertension, angina pectoris, myocardial infarction, coronary artery surgery and congestive heart failure are excluded
- presence of HBsAg and/or HIV
- history of auto-immune disease, including auto-immune hepatitis
- alcohol consumption exceeding 40 grams per day
- acute rejection episode within the 3 months prior to inclusion, or current histological features possibly related to underlying rejection
- hepatocellular carcinoma
- unresolved biliary complication
- renal insufficiency (serum creatinine levels above 200 micromol/l)
- unconjugated bilirubin blood level > 100 micromol/l
- gammaglutamyl transferase > 20 times the upper limit of normal range
- prothrombin time below 60% of control (except in case of oral anti-coagulant therapy)
- neutrophil count less than 1,500/mm3
- platelet count less than 90,000/mm3
- hemoglobin below the lower limit of normal of the testing laboratory
- other organ or bone marrow transplantation
- current neoplasm and/or anti-tumor chemotherapy
- current hepatic arterial thrombosis
- pregnant or breast feeding women; child bearing potential women without adequate contraception throughout the course of therapy
- psychosis or anti-depressant therapy for uncontrolled clinical depression
- clinically significant retinal abnormalities
- thyroid dysfunction (abnormal TSH value with or without clinical symptoms)
- immunosuppressive therapy with OKT3 or any other anti-lymphocyte serum
- drug abuse (heroin, cocaine) or substitution therapy during the 12 months prior to inclusion
- history of ischemic cardiopathy
- interstitial pneumonitis
- previous auto-immune hemolysis and all causes of chronic hemolysis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
Biochemical (normalization of serum transaminases levels),
|
virological (disappearance of HCV RNA from serum)
|
and histological (amelioration of the histological signs of hepatitis) response.
|
二次結果の測定
結果測定 |
---|
Correlation of the above outcome measures with early on-treatment HCV RNA dynamics (if applicable).
|
協力者と研究者
捜査官
- 主任研究者:Francesco Negro, MD、University Hospital, Geneva
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- SASL17
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
C型肝炎の臨床試験
-
Dokuz Eylul UniversityEge University完了MMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/C七面鳥
-
Tripep ABInovio Pharmaceuticalsわからない
-
Hadassah Medical OrganizationXTL Biopharmaceuticals引きこもった
-
Beni-Suef University完了
-
Humanity and Health Research CentreBeijing 302 Hospital完了
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎遺伝子型1 | C型肝炎(HCV) | C型肝炎ウイルス感染症アメリカ, ニュージーランド
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎(HCV) | C型肝炎遺伝子型4 | C型肝炎ウイルス感染症アメリカ
-
Meir Medical Center完了デジタルステレオ光ディスク画像からC/D比を測定する新しい技術を開発 | C/D 測定の観察者内再現性 | C/D 測定値の観測者間のばらつき